The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Anti-Obesity Prescription Drugs Market Research Report 2025
Synopsis
Growing demand for obesity is one of the recent trends in the global Anti-Obesity Prescription Drugs market. Moreover, this trend is further anticipated to drive the global Anti-Obesity Prescription Drugs market over the forecast period. Furthermore, growing obesity due unhealthy food and lifestyle such as intake of drugs due to stress, alcohol leads to growing demand for obesity management resulting in growth of this trend.
The global Anti-Obesity Prescription Drugs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Anti-Obesity Prescription Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Anti-Obesity Prescription Drugs.
Report Scope
The Anti-Obesity Prescription Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Anti-Obesity Prescription Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Anti-Obesity Prescription Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
F Hoffmann La Roche Ltd
Orexigen Therapeutics
Novo Nordisk A/s
Arena Pharmaceuticals
Glaxosmithkline
Vivus
Boehringer Ingelheim
Alizyme
Segment by Type
Pediatric
Adult
Segment by Application
Hospitals Pharmacies
Retail Pharmacies
E-commerce
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Anti-Obesity Prescription Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Anti-Obesity Prescription Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Growing demand for obesity is one of the recent trends in the global Anti-Obesity Prescription Drugs market. Moreover, this trend is further anticipated to drive the global Anti-Obesity Prescription Drugs market over the forecast period. Furthermore, growing obesity due unhealthy food and lifestyle such as intake of drugs due to stress, alcohol leads to growing demand for obesity management resulting in growth of this trend.
The global Anti-Obesity Prescription Drugs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Anti-Obesity Prescription Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Anti-Obesity Prescription Drugs.
Report Scope
The Anti-Obesity Prescription Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Anti-Obesity Prescription Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Anti-Obesity Prescription Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
F Hoffmann La Roche Ltd
Orexigen Therapeutics
Novo Nordisk A/s
Arena Pharmaceuticals
Glaxosmithkline
Vivus
Boehringer Ingelheim
Alizyme
Segment by Type
Pediatric
Adult
Segment by Application
Hospitals Pharmacies
Retail Pharmacies
E-commerce
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Anti-Obesity Prescription Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Anti-Obesity Prescription Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Anti-Obesity Prescription Drugs Market Overview
1.1 Product Overview and Scope of Anti-Obesity Prescription Drugs
1.2 Anti-Obesity Prescription Drugs Segment by Type
1.2.1 Global Anti-Obesity Prescription Drugs Market Value Comparison by Type (2024-2030)
1.2.2 Pediatric
1.2.3 Adult
1.3 Anti-Obesity Prescription Drugs Segment by Application
1.3.1 Global Anti-Obesity Prescription Drugs Market Value by Application: (2024-2030)
1.3.2 Hospitals Pharmacies
1.3.3 Retail Pharmacies
1.3.4 E-commerce
1.4 Global Anti-Obesity Prescription Drugs Market Size Estimates and Forecasts
1.4.1 Global Anti-Obesity Prescription Drugs Revenue 2019-2030
1.4.2 Global Anti-Obesity Prescription Drugs Sales 2019-2030
1.4.3 Global Anti-Obesity Prescription Drugs Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Anti-Obesity Prescription Drugs Market Competition by Manufacturers
2.1 Global Anti-Obesity Prescription Drugs Sales Market Share by Manufacturers (2019-2024)
2.2 Global Anti-Obesity Prescription Drugs Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Anti-Obesity Prescription Drugs Average Price by Manufacturers (2019-2024)
2.4 Global Anti-Obesity Prescription Drugs Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Anti-Obesity Prescription Drugs, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Anti-Obesity Prescription Drugs, Product Type & Application
2.7 Anti-Obesity Prescription Drugs Market Competitive Situation and Trends
2.7.1 Anti-Obesity Prescription Drugs Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Anti-Obesity Prescription Drugs Players Market Share by Revenue
2.7.3 Global Anti-Obesity Prescription Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Anti-Obesity Prescription Drugs Retrospective Market Scenario by Region
3.1 Global Anti-Obesity Prescription Drugs Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Anti-Obesity Prescription Drugs Global Anti-Obesity Prescription Drugs Sales by Region: 2019-2030
3.2.1 Global Anti-Obesity Prescription Drugs Sales by Region: 2019-2024
3.2.2 Global Anti-Obesity Prescription Drugs Sales by Region: 2025-2030
3.3 Global Anti-Obesity Prescription Drugs Global Anti-Obesity Prescription Drugs Revenue by Region: 2019-2030
3.3.1 Global Anti-Obesity Prescription Drugs Revenue by Region: 2019-2024
3.3.2 Global Anti-Obesity Prescription Drugs Revenue by Region: 2025-2030
3.4 North America Anti-Obesity Prescription Drugs Market Facts & Figures by Country
3.4.1 North America Anti-Obesity Prescription Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Anti-Obesity Prescription Drugs Sales by Country (2019-2030)
3.4.3 North America Anti-Obesity Prescription Drugs Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Anti-Obesity Prescription Drugs Market Facts & Figures by Country
3.5.1 Europe Anti-Obesity Prescription Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Anti-Obesity Prescription Drugs Sales by Country (2019-2030)
3.5.3 Europe Anti-Obesity Prescription Drugs Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Anti-Obesity Prescription Drugs Market Facts & Figures by Country
3.6.1 Asia Pacific Anti-Obesity Prescription Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Anti-Obesity Prescription Drugs Sales by Country (2019-2030)
3.6.3 Asia Pacific Anti-Obesity Prescription Drugs Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Anti-Obesity Prescription Drugs Market Facts & Figures by Country
3.7.1 Latin America Anti-Obesity Prescription Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Anti-Obesity Prescription Drugs Sales by Country (2019-2030)
3.7.3 Latin America Anti-Obesity Prescription Drugs Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Anti-Obesity Prescription Drugs Market Facts & Figures by Country
3.8.1 Middle East and Africa Anti-Obesity Prescription Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Anti-Obesity Prescription Drugs Sales by Country (2019-2030)
3.8.3 Middle East and Africa Anti-Obesity Prescription Drugs Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Anti-Obesity Prescription Drugs Sales by Type (2019-2030)
4.1.1 Global Anti-Obesity Prescription Drugs Sales by Type (2019-2024)
4.1.2 Global Anti-Obesity Prescription Drugs Sales by Type (2025-2030)
4.1.3 Global Anti-Obesity Prescription Drugs Sales Market Share by Type (2019-2030)
4.2 Global Anti-Obesity Prescription Drugs Revenue by Type (2019-2030)
4.2.1 Global Anti-Obesity Prescription Drugs Revenue by Type (2019-2024)
4.2.2 Global Anti-Obesity Prescription Drugs Revenue by Type (2025-2030)
4.2.3 Global Anti-Obesity Prescription Drugs Revenue Market Share by Type (2019-2030)
4.3 Global Anti-Obesity Prescription Drugs Price by Type (2019-2030)
5 Segment by Application
5.1 Global Anti-Obesity Prescription Drugs Sales by Application (2019-2030)
5.1.1 Global Anti-Obesity Prescription Drugs Sales by Application (2019-2024)
5.1.2 Global Anti-Obesity Prescription Drugs Sales by Application (2025-2030)
5.1.3 Global Anti-Obesity Prescription Drugs Sales Market Share by Application (2019-2030)
5.2 Global Anti-Obesity Prescription Drugs Revenue by Application (2019-2030)
5.2.1 Global Anti-Obesity Prescription Drugs Revenue by Application (2019-2024)
5.2.2 Global Anti-Obesity Prescription Drugs Revenue by Application (2025-2030)
5.2.3 Global Anti-Obesity Prescription Drugs Revenue Market Share by Application (2019-2030)
5.3 Global Anti-Obesity Prescription Drugs Price by Application (2019-2030)
6 Key Companies Profiled
6.1 F Hoffmann La Roche Ltd
6.1.1 F Hoffmann La Roche Ltd Corporation Information
6.1.2 F Hoffmann La Roche Ltd Description and Business Overview
6.1.3 F Hoffmann La Roche Ltd Anti-Obesity Prescription Drugs Sales, Revenue and Gross Margin (2019-2024)
6.1.4 F Hoffmann La Roche Ltd Anti-Obesity Prescription Drugs Product Portfolio
6.1.5 F Hoffmann La Roche Ltd Recent Developments/Updates
6.2 Orexigen Therapeutics
6.2.1 Orexigen Therapeutics Corporation Information
6.2.2 Orexigen Therapeutics Description and Business Overview
6.2.3 Orexigen Therapeutics Anti-Obesity Prescription Drugs Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Orexigen Therapeutics Anti-Obesity Prescription Drugs Product Portfolio
6.2.5 Orexigen Therapeutics Recent Developments/Updates
6.3 Novo Nordisk A/s
6.3.1 Novo Nordisk A/s Corporation Information
6.3.2 Novo Nordisk A/s Description and Business Overview
6.3.3 Novo Nordisk A/s Anti-Obesity Prescription Drugs Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Novo Nordisk A/s Anti-Obesity Prescription Drugs Product Portfolio
6.3.5 Novo Nordisk A/s Recent Developments/Updates
6.4 Arena Pharmaceuticals
6.4.1 Arena Pharmaceuticals Corporation Information
6.4.2 Arena Pharmaceuticals Description and Business Overview
6.4.3 Arena Pharmaceuticals Anti-Obesity Prescription Drugs Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Arena Pharmaceuticals Anti-Obesity Prescription Drugs Product Portfolio
6.4.5 Arena Pharmaceuticals Recent Developments/Updates
6.5 Glaxosmithkline
6.5.1 Glaxosmithkline Corporation Information
6.5.2 Glaxosmithkline Description and Business Overview
6.5.3 Glaxosmithkline Anti-Obesity Prescription Drugs Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Glaxosmithkline Anti-Obesity Prescription Drugs Product Portfolio
6.5.5 Glaxosmithkline Recent Developments/Updates
6.6 Vivus
6.6.1 Vivus Corporation Information
6.6.2 Vivus Description and Business Overview
6.6.3 Vivus Anti-Obesity Prescription Drugs Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Vivus Anti-Obesity Prescription Drugs Product Portfolio
6.6.5 Vivus Recent Developments/Updates
6.7 Boehringer Ingelheim
6.6.1 Boehringer Ingelheim Corporation Information
6.6.2 Boehringer Ingelheim Description and Business Overview
6.6.3 Boehringer Ingelheim Anti-Obesity Prescription Drugs Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Boehringer Ingelheim Anti-Obesity Prescription Drugs Product Portfolio
6.7.5 Boehringer Ingelheim Recent Developments/Updates
6.8 Alizyme
6.8.1 Alizyme Corporation Information
6.8.2 Alizyme Description and Business Overview
6.8.3 Alizyme Anti-Obesity Prescription Drugs Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Alizyme Anti-Obesity Prescription Drugs Product Portfolio
6.8.5 Alizyme Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Anti-Obesity Prescription Drugs Industry Chain Analysis
7.2 Anti-Obesity Prescription Drugs Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Anti-Obesity Prescription Drugs Production Mode & Process
7.4 Anti-Obesity Prescription Drugs Sales and Marketing
7.4.1 Anti-Obesity Prescription Drugs Sales Channels
7.4.2 Anti-Obesity Prescription Drugs Distributors
7.5 Anti-Obesity Prescription Drugs Customers
8 Anti-Obesity Prescription Drugs Market Dynamics
8.1 Anti-Obesity Prescription Drugs Industry Trends
8.2 Anti-Obesity Prescription Drugs Market Drivers
8.3 Anti-Obesity Prescription Drugs Market Challenges
8.4 Anti-Obesity Prescription Drugs Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of TablesList of Tables
Table 1. Global Anti-Obesity Prescription Drugs Market Value Comparison by Type (2024-2030) & (US$ Million)
Table 2. Global Anti-Obesity Prescription Drugs Market Value Comparison by Application (2024-2030) & (US$ Million)
Table 3. Global Anti-Obesity Prescription Drugs Market Competitive Situation by Manufacturers in 2023
Table 4. Global Anti-Obesity Prescription Drugs Sales (K Units) of Key Manufacturers (2019-2024)
Table 5. Global Anti-Obesity Prescription Drugs Sales Market Share by Manufacturers (2019-2024)
Table 6. Global Anti-Obesity Prescription Drugs Revenue (US$ Million) by Manufacturers (2019-2024)
Table 7. Global Anti-Obesity Prescription Drugs Revenue Share by Manufacturers (2019-2024)
Table 8. Global Market Anti-Obesity Prescription Drugs Average Price (US$/Unit) of Key Manufacturers (2019-2024)
Table 9. Global Key Players of Anti-Obesity Prescription Drugs, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of Anti-Obesity Prescription Drugs, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Anti-Obesity Prescription Drugs, Product Type & Application
Table 12. Global Key Manufacturers of Anti-Obesity Prescription Drugs, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Anti-Obesity Prescription Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Anti-Obesity Prescription Drugs as of 2023)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Anti-Obesity Prescription Drugs Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 17. Global Anti-Obesity Prescription Drugs Sales by Region (2019-2024) & (K Units)
Table 18. Global Anti-Obesity Prescription Drugs Sales Market Share by Region (2019-2024)
Table 19. Global Anti-Obesity Prescription Drugs Sales by Region (2025-2030) & (K Units)
Table 20. Global Anti-Obesity Prescription Drugs Sales Market Share by Region (2025-2030)
Table 21. Global Anti-Obesity Prescription Drugs Revenue by Region (2019-2024) & (US$ Million)
Table 22. Global Anti-Obesity Prescription Drugs Revenue Market Share by Region (2019-2024)
Table 23. Global Anti-Obesity Prescription Drugs Revenue by Region (2025-2030) & (US$ Million)
Table 24. Global Anti-Obesity Prescription Drugs Revenue Market Share by Region (2025-2030)
Table 25. North America Anti-Obesity Prescription Drugs Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 26. North America Anti-Obesity Prescription Drugs Sales by Country (2019-2024) & (K Units)
Table 27. North America Anti-Obesity Prescription Drugs Sales by Country (2025-2030) & (K Units)
Table 28. North America Anti-Obesity Prescription Drugs Revenue by Country (2019-2024) & (US$ Million)
Table 29. North America Anti-Obesity Prescription Drugs Revenue by Country (2025-2030) & (US$ Million)
Table 30. Europe Anti-Obesity Prescription Drugs Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 31. Europe Anti-Obesity Prescription Drugs Sales by Country (2019-2024) & (K Units)
Table 32. Europe Anti-Obesity Prescription Drugs Sales by Country (2025-2030) & (K Units)
Table 33. Europe Anti-Obesity Prescription Drugs Revenue by Country (2019-2024) & (US$ Million)
Table 34. Europe Anti-Obesity Prescription Drugs Revenue by Country (2025-2030) & (US$ Million)
Table 35. Asia Pacific Anti-Obesity Prescription Drugs Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 36. Asia Pacific Anti-Obesity Prescription Drugs Sales by Region (2019-2024) & (K Units)
Table 37. Asia Pacific Anti-Obesity Prescription Drugs Sales by Region (2025-2030) & (K Units)
Table 38. Asia Pacific Anti-Obesity Prescription Drugs Revenue by Region (2019-2024) & (US$ Million)
Table 39. Asia Pacific Anti-Obesity Prescription Drugs Revenue by Region (2025-2030) & (US$ Million)
Table 40. Latin America Anti-Obesity Prescription Drugs Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 41. Latin America Anti-Obesity Prescription Drugs Sales by Country (2019-2024) & (K Units)
Table 42. Latin America Anti-Obesity Prescription Drugs Sales by Country (2025-2030) & (K Units)
Table 43. Latin America Anti-Obesity Prescription Drugs Revenue by Country (2019-2024) & (US$ Million)
Table 44. Latin America Anti-Obesity Prescription Drugs Revenue by Country (2025-2030) & (US$ Million)
Table 45. Middle East & Africa Anti-Obesity Prescription Drugs Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 46. Middle East & Africa Anti-Obesity Prescription Drugs Sales by Country (2019-2024) & (K Units)
Table 47. Middle East & Africa Anti-Obesity Prescription Drugs Sales by Country (2025-2030) & (K Units)
Table 48. Middle East & Africa Anti-Obesity Prescription Drugs Revenue by Country (2019-2024) & (US$ Million)
Table 49. Middle East & Africa Anti-Obesity Prescription Drugs Revenue by Country (2025-2030) & (US$ Million)
Table 50. Global Anti-Obesity Prescription Drugs Sales (K Units) by Type (2019-2024)
Table 51. Global Anti-Obesity Prescription Drugs Sales (K Units) by Type (2025-2030)
Table 52. Global Anti-Obesity Prescription Drugs Sales Market Share by Type (2019-2024)
Table 53. Global Anti-Obesity Prescription Drugs Sales Market Share by Type (2025-2030)
Table 54. Global Anti-Obesity Prescription Drugs Revenue (US$ Million) by Type (2019-2024)
Table 55. Global Anti-Obesity Prescription Drugs Revenue (US$ Million) by Type (2025-2030)
Table 56. Global Anti-Obesity Prescription Drugs Revenue Market Share by Type (2019-2024)
Table 57. Global Anti-Obesity Prescription Drugs Revenue Market Share by Type (2025-2030)
Table 58. Global Anti-Obesity Prescription Drugs Price (US$/Unit) by Type (2019-2024)
Table 59. Global Anti-Obesity Prescription Drugs Price (US$/Unit) by Type (2025-2030)
Table 60. Global Anti-Obesity Prescription Drugs Sales (K Units) by Application (2019-2024)
Table 61. Global Anti-Obesity Prescription Drugs Sales (K Units) by Application (2025-2030)
Table 62. Global Anti-Obesity Prescription Drugs Sales Market Share by Application (2019-2024)
Table 63. Global Anti-Obesity Prescription Drugs Sales Market Share by Application (2025-2030)
Table 64. Global Anti-Obesity Prescription Drugs Revenue (US$ Million) by Application (2019-2024)
Table 65. Global Anti-Obesity Prescription Drugs Revenue (US$ Million) by Application (2025-2030)
Table 66. Global Anti-Obesity Prescription Drugs Revenue Market Share by Application (2019-2024)
Table 67. Global Anti-Obesity Prescription Drugs Revenue Market Share by Application (2025-2030)
Table 68. Global Anti-Obesity Prescription Drugs Price (US$/Unit) by Application (2019-2024)
Table 69. Global Anti-Obesity Prescription Drugs Price (US$/Unit) by Application (2025-2030)
Table 70. F Hoffmann La Roche Ltd Corporation Information
Table 71. F Hoffmann La Roche Ltd Description and Business Overview
Table 72. F Hoffmann La Roche Ltd Anti-Obesity Prescription Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 73. F Hoffmann La Roche Ltd Anti-Obesity Prescription Drugs Product
Table 74. F Hoffmann La Roche Ltd Recent Developments/Updates
Table 75. Orexigen Therapeutics Corporation Information
Table 76. Orexigen Therapeutics Description and Business Overview
Table 77. Orexigen Therapeutics Anti-Obesity Prescription Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 78. Orexigen Therapeutics Anti-Obesity Prescription Drugs Product
Table 79. Orexigen Therapeutics Recent Developments/Updates
Table 80. Novo Nordisk A/s Corporation Information
Table 81. Novo Nordisk A/s Description and Business Overview
Table 82. Novo Nordisk A/s Anti-Obesity Prescription Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 83. Novo Nordisk A/s Anti-Obesity Prescription Drugs Product
Table 84. Novo Nordisk A/s Recent Developments/Updates
Table 85. Arena Pharmaceuticals Corporation Information
Table 86. Arena Pharmaceuticals Description and Business Overview
Table 87. Arena Pharmaceuticals Anti-Obesity Prescription Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 88. Arena Pharmaceuticals Anti-Obesity Prescription Drugs Product
Table 89. Arena Pharmaceuticals Recent Developments/Updates
Table 90. Glaxosmithkline Corporation Information
Table 91. Glaxosmithkline Description and Business Overview
Table 92. Glaxosmithkline Anti-Obesity Prescription Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 93. Glaxosmithkline Anti-Obesity Prescription Drugs Product
Table 94. Glaxosmithkline Recent Developments/Updates
Table 95. Vivus Corporation Information
Table 96. Vivus Description and Business Overview
Table 97. Vivus Anti-Obesity Prescription Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 98. Vivus Anti-Obesity Prescription Drugs Product
Table 99. Vivus Recent Developments/Updates
Table 100. Boehringer Ingelheim Corporation Information
Table 101. Boehringer Ingelheim Description and Business Overview
Table 102. Boehringer Ingelheim Anti-Obesity Prescription Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 103. Boehringer Ingelheim Anti-Obesity Prescription Drugs Product
Table 104. Boehringer Ingelheim Recent Developments/Updates
Table 105. Alizyme Corporation Information
Table 106. Alizyme Description and Business Overview
Table 107. Alizyme Anti-Obesity Prescription Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 108. Alizyme Anti-Obesity Prescription Drugs Product
Table 109. Alizyme Recent Developments/Updates
Table 110. Key Raw Materials Lists
Table 111. Raw Materials Key Suppliers Lists
Table 112. Anti-Obesity Prescription Drugs Distributors List
Table 113. Anti-Obesity Prescription Drugs Customers List
Table 114. Anti-Obesity Prescription Drugs Market Trends
Table 115. Anti-Obesity Prescription Drugs Market Drivers
Table 116. Anti-Obesity Prescription Drugs Market Challenges
Table 117. Anti-Obesity Prescription Drugs Market Restraints
Table 118. Research Programs/Design for This Report
Table 119. Key Data Information from Secondary Sources
Table 120. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Anti-Obesity Prescription Drugs
Figure 2. Global Anti-Obesity Prescription Drugs Market Value Comparison by Type (2024-2030) & (US$ Million)
Figure 3. Global Anti-Obesity Prescription Drugs Market Share by Type in 2023 & 2030
Figure 4. Pediatric Product Picture
Figure 5. Adult Product Picture
Figure 6. Global Anti-Obesity Prescription Drugs Market Value Comparison by Application (2024-2030) & (US$ Million)
Figure 7. Global Anti-Obesity Prescription Drugs Market Share by Application in 2023 & 2030
Figure 8. Hospitals Pharmacies
Figure 9. Retail Pharmacies
Figure 10. E-commerce
Figure 11. Global Anti-Obesity Prescription Drugs Revenue, (US$ Million), 2019 VS 2023 VS 2030
Figure 12. Global Anti-Obesity Prescription Drugs Market Size (2019-2030) & (US$ Million)
Figure 13. Global Anti-Obesity Prescription Drugs Sales (2019-2030) & (K Units)
Figure 14. Global Anti-Obesity Prescription Drugs Average Price (US$/Unit) & (2019-2030)
Figure 15. Anti-Obesity Prescription Drugs Report Years Considered
Figure 16. Anti-Obesity Prescription Drugs Sales Share by Manufacturers in 2023
Figure 17. Global Anti-Obesity Prescription Drugs Revenue Share by Manufacturers in 2023
Figure 18. The Global 5 and 10 Largest Anti-Obesity Prescription Drugs Players: Market Share by Revenue in 2023
Figure 19. Anti-Obesity Prescription Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2019 VS 2023
Figure 20. Global Anti-Obesity Prescription Drugs Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Figure 21. North America Anti-Obesity Prescription Drugs Sales Market Share by Country (2019-2030)
Figure 22. North America Anti-Obesity Prescription Drugs Revenue Market Share by Country (2019-2030)
Figure 23. U.S. Anti-Obesity Prescription Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 24. Canada Anti-Obesity Prescription Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 25. Europe Anti-Obesity Prescription Drugs Sales Market Share by Country (2019-2030)
Figure 26. Europe Anti-Obesity Prescription Drugs Revenue Market Share by Country (2019-2030)
Figure 27. Germany Anti-Obesity Prescription Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 28. France Anti-Obesity Prescription Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 29. U.K. Anti-Obesity Prescription Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 30. Italy Anti-Obesity Prescription Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 31. Russia Anti-Obesity Prescription Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 32. Asia Pacific Anti-Obesity Prescription Drugs Sales Market Share by Region (2019-2030)
Figure 33. Asia Pacific Anti-Obesity Prescription Drugs Revenue Market Share by Region (2019-2030)
Figure 34. China Anti-Obesity Prescription Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 35. Japan Anti-Obesity Prescription Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 36. South Korea Anti-Obesity Prescription Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 37. India Anti-Obesity Prescription Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 38. Australia Anti-Obesity Prescription Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 39. Taiwan Anti-Obesity Prescription Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 40. Indonesia Anti-Obesity Prescription Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 41. Thailand Anti-Obesity Prescription Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 42. Malaysia Anti-Obesity Prescription Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 43. Philippines Anti-Obesity Prescription Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 44. Latin America Anti-Obesity Prescription Drugs Sales Market Share by Country (2019-2030)
Figure 45. Latin America Anti-Obesity Prescription Drugs Revenue Market Share by Country (2019-2030)
Figure 46. Mexico Anti-Obesity Prescription Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 47. Brazil Anti-Obesity Prescription Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 48. Argentina Anti-Obesity Prescription Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 49. Middle East & Africa Anti-Obesity Prescription Drugs Sales Market Share by Country (2019-2030)
Figure 50. Middle East & Africa Anti-Obesity Prescription Drugs Revenue Market Share by Country (2019-2030)
Figure 51. Turkey Anti-Obesity Prescription Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 52. Saudi Arabia Anti-Obesity Prescription Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 53. U.A.E Anti-Obesity Prescription Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 54. Global Sales Market Share of Anti-Obesity Prescription Drugs by Type (2019-2030)
Figure 55. Global Revenue Market Share of Anti-Obesity Prescription Drugs by Type (2019-2030)
Figure 56. Global Anti-Obesity Prescription Drugs Price (US$/Unit) by Type (2019-2030)
Figure 57. Global Sales Market Share of Anti-Obesity Prescription Drugs by Application (2019-2030)
Figure 58. Global Revenue Market Share of Anti-Obesity Prescription Drugs by Application (2019-2030)
Figure 59. Global Anti-Obesity Prescription Drugs Price (US$/Unit) by Application (2019-2030)
Figure 60. Anti-Obesity Prescription Drugs Value Chain
Figure 61. Anti-Obesity Prescription Drugs Production Process
Figure 62. Channels of Distribution (Direct Vs Distribution)
Figure 63. Distributors Profiles
Figure 64. Bottom-up and Top-down Approaches for This Report
Figure 65. Data Triangulation
Figure 66. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
